Paeds Vivas · fetal-neonatal-and-perinatal
Haemolytic disease of the fetus and newborn — branching viva
Viva on the IgG-mediated mechanism, anti-D prophylaxis, MCA-PSV surveillance, intrauterine transfusion, and the postnatal phototherapy-IVIG-exchange ladder.
On this page
Study tools
Target exams
Branch 1 — Mechanism and prevention
The examiner opens: "Explain how this woman became sensitised and how it could have been prevented." A strong candidate traces the fetomaternal haemorrhage that exposed her to fetal RhD-positive cells, the maternal immune response producing anti-D IgG, and the fact that this crosses the placenta from about 16 weeks via the neonatal Fc receptor to bind and destroy fetal red cells. The prevention is antenatal and postnatal anti-D immunoglobulin to Rh-negative mothers, which suppresses sensitisation, and anti-D after any sensitising event such as a miscarriage — the Crowther Cochrane reviews established the evidence base. [1]
References5ShowHide
- [1]Crowther CA, Middleton P Anti-D administration in pregnancy for preventing Rhesus alloimmunisation. Cochrane Database Syst Rev, 2013.PMID 23450526
- [3]Mari G, Deter RL, Carpenter RL, et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. N Engl J Med, 2000.PMID 10620643
- [4]Mari G, Norton ME, Stone J, Berghella V, Sciscione AC, Tate D, Schenone MH Society for Maternal-Fetal Medicine (SMFM) Clinical Guideline #8: the fetus at risk for anemia--diagnosis and management. Am J Obstet Gynecol, 2015.PMID 25824811
- [5]American Academy of Pediatrics Subcommittee on Hyperbilirubinemia Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics, 2004.PMID 15231951
- [8]Zwiers C, Scheffer-Rath ME, Lopriore E, de Haas M, Liley HG Immunoglobulin for alloimmune hemolytic disease in neonates. Cochrane Database Syst Rev, 2018.PMID 29551014